Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferran Vall-Llovera

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Leukemia Research|March 26, 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemiaJosep-Maria Ribera, Olga García, Cristina Gil, et al.
Leukemia & Lymphoma|January 9, 2014
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsBlanca Xicoy, Josep-Maria Ribera, Markus Müller, et al.
Cancer Medicine|February 6, 2020
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trialJosep-Maria Ribera, Mireia Morgades, Pau Montesinos, et al.
European Journal of Haematology|September 30, 2018
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trialsPere Barba, Mireia Morgades, Pau Montesinos, et al.
Leukemia & Lymphoma|November 23, 2017
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemiaJosep-Maria Ribera, Mireia Morgades, Pau Montesinos, et al.
Blood Advances|December 15, 2021
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocolAlex Bataller, Ana Garrido, Francesca Guijarro, et al.
Haematologica|August 10, 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trialJosep-Maria Ribera, Mireia Morgades, Olga Garcia-Calduch, et al.
Cancers|April 12, 2022
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry ExperienceJorge Labrador, Miriam Saiz-Rodríguez, Dunia de Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 28, 2020
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal ChemotherapyJosep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, et al.
Leukemia Research|June 17, 2021
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)Eulàlia Genescà, Mireia Morgades, Celia González-Gil, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Leukemia Research|March 26, 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemiaJosep-Maria Ribera, Olga García, Cristina Gil, et al.
Leukemia & Lymphoma|January 9, 2014
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsBlanca Xicoy, Josep-Maria Ribera, Markus Müller, et al.
Cancer Medicine|February 6, 2020
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trialJosep-Maria Ribera, Mireia Morgades, Pau Montesinos, et al.
European Journal of Haematology|September 30, 2018
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trialsPere Barba, Mireia Morgades, Pau Montesinos, et al.
Leukemia & Lymphoma|November 23, 2017
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemiaJosep-Maria Ribera, Mireia Morgades, Pau Montesinos, et al.
Blood Advances|December 15, 2021
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocolAlex Bataller, Ana Garrido, Francesca Guijarro, et al.
Haematologica|August 10, 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trialJosep-Maria Ribera, Mireia Morgades, Olga Garcia-Calduch, et al.
Cancers|April 12, 2022
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry ExperienceJorge Labrador, Miriam Saiz-Rodríguez, Dunia de Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 28, 2020
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal ChemotherapyJosep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, et al.
Leukemia Research|June 17, 2021
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)Eulàlia Genescà, Mireia Morgades, Celia González-Gil, et al.
Pageof 3